التفاصيل البيبلوغرافية
| العنوان: |
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. |
| المؤلفون: |
Wohl, DA1, Bhatti, L2, Small, CB3, Edelstein, H4, Zhao, HH5, Margolis, DA5, DeJesus, E6, Weinberg, WG7, Ross, LL8, Shaefer, MS8 |
| المصدر: |
HIV Medicine. Feb2016, Vol. 17 Issue 2, p106-117. 12p. |
| مصطلحات موضوعية: |
*BIOMARKERS, *HIV, *HIV infections, *HIV-positive persons, *STATISTICAL sampling, *LAMIVUDINE, *DATA analysis software, *ABACAVIR, *ABACAVIR-lamivudine (Drug), *ATAZANAVIR, *DESCRIPTIVE statistics |
| مستخلص: |
Objectives HIV treatment guidelines endorse switching or simplification of antiretroviral therapy in therapy-experienced patients with suppressed viraemia; ritonavir discontinuation may also enhance tolerability and reduce long-term adverse events ( AEs). This open-label, multicentre, noninferiority study enrolled HIV-1-infected, treatment-experienced adults with confirmed HIV-1 RNA ≤ 75 HIV-1 RNA copies/mL currently receiving tenofovir/emtricitabine + atazanavir/ritonavir ( TDF/ FTC + ATV/r) for ≥ 6 months with no reported history of virological failure. Methods Participants were randomized 1:2 to continue current treatment or switch to abacavir/lamivudine + atazanavir ( ABC/3TC + ATV). Endpoints included the proportion of participants with HIV-1 RNA < 50 copies/mL by time to loss of virological response ( TLOVR), AEs, fasting lipids, and inflammatory, coagulation, bone and renal biomarkers. Results After 48 weeks, 76% (152 of 199) of ABC/3TC + ATV-treated and 79% (77 of 97) of TDF/ FTC + ATV/r-treated participants had HIV-1 RNA < 50 copies/mL ( TLOVR; P = 0.564). Other efficacy analyses yielded similar results. Rates of new grade 2-4 AEs were 45% in both groups, but an excess of hyperbilirubinaemia made the rate of treatment-emergent grade 3-4 laboratory abnormalities higher with TDF/ FTC + ATV/r (36%) compared with ABC/3TC + ATV (19%). Most fasting lipid levels remained stable over time; high-density lipoprotein ( HDL) cholesterol increased modestly in ABC/3TC + ATV-treated participants. Bone and renal biomarkers improved significantly between baseline and week 48 in participants taking ABC/3TC + ATV and were stable in participants taking TDF/ FTC + ATV/r. No significant changes occurred in any inflammatory or coagulation biomarker within or between treatment groups. Conclusions The ABC/3TC + ATV treatment-switch group had similar viral suppression rates up to 48 weeks to the TDF/ FTC + ATV/r comparator group, with lower rates of moderate- to high-grade hyperbilirubinaemia and improvements in bone and renal biomarkers. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder